# SECURITIES AND EXCHANGE COMMISSION
# Washington, D.C. 20549

## SCHEDULE 13D

Under the Securities Exchange Act of 1934

**(Amendment No. 9)***

**LeonaBio, Inc.**

**(Name of Issuer)**

**Common Stock, $0.0001 par value**

**(Title of Class of Securities)**

**(CUSIP Number)**

**Alexander Rakitin**
**Perceptive Advisors LLC, 51 Astor Place, 10th Floor**
**New York, NY, 10003**
**(646) 205-5345**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**10/26/2026**

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

**CUSIP No.**

| | |
|---|---|
| 1 | Name of reporting person<br><br>Perceptive Advisors LLC |
| 2 | Check the appropriate box if a member of a Group (See Instructions) |

☐ (a)
☑ (b)

3 SEC use only

Source of funds (See Instructions)

4 AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5 ☑

Citizenship or place of organization

6 DELAWARE

| | | |
|---|---|---|
| Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power<br>0.00 |
| | 8 | Shared Voting Power<br>1,889,403.00 |
| | 9 | Sole Dispositive Power<br>0.00 |
| | 10 | Shared Dispositive Power<br>1,889,403.00 |

Aggregate amount beneficially owned by each reporting person

11 1,889,403.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12 ☐

Percent of class represented by amount in Row (11)

13 19.99 %

Type of Reporting Person (See Instructions)

14 IA

SCHEDULE 13D

**CUSIP No.**

Name of reporting person

1 Joseph Edelman

Check the appropriate box if a member of a Group (See Instructions)

2 ☐ (a)
☑ (b)

3 SEC use only

Source of funds (See Instructions)

4 AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5 ☑

Citizenship or place of organization

6 UNITED STATES

| | | |
|---|---|---|
| Number of | 7 | Sole Voting Power |

| | | |
|---|---|---|
| Shares Beneficially Owned by Each Reporting Person With: | | 0.00 |
| | 8 | Shared Voting Power<br>1,889,403.00 |
| | 9 | Sole Dispositive Power<br>0.00 |
| | 10 | Shared Dispositive Power<br>1,889,403.00 |
| 11 | | Aggregate amount beneficially owned by each reporting person<br>1,889,403.00 |
| 12 | | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>☐ |
| 13 | | Percent of class represented by amount in Row (11)<br>19.99 % |
| 14 | | Type of Reporting Person (See Instructions)<br>IN |

SCHEDULE 13D

**CUSIP No.**

| | | |
|---|---|---|
| 1 | | Name of reporting person<br>Perceptive Life Sciences Master Fund, Ltd. |
| 2 | | Check the appropriate box if a member of a Group (See Instructions)<br>☐ (a)<br>☑ (b) |
| 3 | | SEC use only |
| 4 | | Source of funds (See Instructions)<br>WC |
| 5 | | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>☑ |
| 6 | | Citizenship or place of organization<br>CAYMAN ISLANDS |
| Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power<br>0.00 |
| | 8 | Shared Voting Power<br>1,559,647.00 |
| | 9 | Sole Dispositive Power<br>0.00 |
| | 10 | Shared Dispositive Power<br>1,559,647.00 |
| 11 | | Aggregate amount beneficially owned by each reporting person |

1,559,647.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

☐

Percent of class represented by amount in Row (11)

13

16.5 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

**CUSIP No.**

Name of reporting person

1

Perceptive Xontogeny Venture Fund II, LP

Check the appropriate box if a member of a Group (See Instructions)

2

☐ (a)
☑ (b)

3 SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

☐

Citizenship or place of organization

6

DELAWARE

| Number of Shares Beneficially Owned by Each Reporting Person With: | |
|---|---|
| 7 | Sole Voting Power<br>0.00 |
| 8 | Shared Voting Power<br>359,837.00 |
| 9 | Sole Dispositive Power<br>0.00 |
| 10 | Shared Dispositive Power<br>359,837.00 |

Aggregate amount beneficially owned by each reporting person

11

359,837.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

☐

Percent of class represented by amount in Row (11)

13

3.8 %

Type of Reporting Person (See Instructions)

14

PN

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, $0.0001 par value

(b) Name of Issuer:

LeonaBio, Inc.

(c) Address of Issuer's Principal Executive Offices:

18706 North Creek Parkway, Suite 104, Bothell, WASHINGTON , 98011.

Item 5. Interest in Securities of the Issuer

(a) Item 5 of the Schedule 13D is amended and supplemented as follows:

(c) On October 26, 2026, PXV II received Sermonix Pre-Funded Warrants exercisable for 2,352,932 shares of Common Stock pursuant to the previously disclosed distribution of securities to owners of Sermonix's common stock. The Sermonix Pre-Funded Warrants are not exercisable to the extent that such exercise would result in beneficial ownership in excess of 19.99% of the outstanding shares of Common Stock of the Issuer.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Member
Date: 10/26/2026

Joseph Edelman

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman
Date: 10/26/2026

Perceptive Life Sciences Master Fund, Ltd.

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Member
Date: 10/26/2026

Perceptive Xontogeny Venture Fund II, LP

Signature: /s/ Joseph Edelman
Name/Title: Joseph Edelman, Managing Partner
Date: 10/26/2026